Entrada Therapeutics Inc
TRDA6.020USD
+0.220+3.79%
交易中 （美东）报价延迟15分钟
228.41M总市值
9.22市盈率 TTM
关于 Entrada Therapeutics Inc 公司
Entrada Therapeutics, Inc. 是一家临床阶段的生物制药公司，旨在通过开发一类药物来改变患者的生活，这些药物可以作用于长期以来被认为无法接近的细胞内靶点。该公司的内体逃逸载体 (EEV) 疗法旨在将一系列治疗药物高效地输送到各种器官和组织中，从而提高治疗指数。通过其专有的、高度通用和模块化的 EEV 平台 (EEV 平台)，该公司正在构建一个强大的治疗候选药物开发组合。其首批两种候选药物 ENTR-601-44 和 VX-670 正在临床试验中。用于治疗 1 型营养不良症 (DM1) 的 VX-670 旨在阻断信使 RNA (mRNA) 中的三联体重复序列。ENTR-601-44 正处于 I 期临床试验中。该公司还宣布在其杜氏肌营养不良症特许经营权范围内选定其他临床候选药物 ENTR-601-45 和 ENTR-601-50。
公司简介
公司代码TRDA
公司名称Entrada Therapeutics Inc
上市日期Oct 29, 2021
CEOMr. Dipal Doshi
员工数量183
证券类型Ordinary Share
年结日Oct 29
公司地址One Design Center Place
城市BOSTON
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编02210
电话18573051825
网址https://www.entradatx.com/
公司代码TRDA
上市日期Oct 29, 2021
CEOMr. Dipal Doshi
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Peter S. Kim, Ph.D.
Dr. Peter S. Kim, Ph.D.
Director
Director
104.33K
-10.60%
Dr. Natarajan Sethuraman, Ph.D.
Dr. Natarajan Sethuraman, Ph.D.
President of Research and Development
President of Research and Development
82.24K
-31.79%
Mr. Kory James Wentworth, CPA
Mr. Kory James Wentworth, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
31.84K
-27.89%
Mr. Nathan J. Dowden
Mr. Nathan J. Dowden
President, Chief Operating Officer
President, Chief Operating Officer
11.80K
-77.74%
Ms. Gina Chapman
Ms. Gina Chapman
Independent Director
Independent Director
--
--
Dr. Bernhardt (Bernie) Zeiher, M.D.
Dr. Bernhardt (Bernie) Zeiher, M.D.
Independent Director
Independent Director
--
--
Dr. Kush M. Parmar, M.D., Ph.D.
Dr. Kush M. Parmar, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Dipal Doshi
Mr. Dipal Doshi
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Mary T. Thistle, CPA
Ms. Mary T. Thistle, CPA
Independent Director
Independent Director
--
--
Dr. Mahalakshmi (Maha) Radhakrishnan, M.D.
Dr. Mahalakshmi (Maha) Radhakrishnan, M.D.
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Peter S. Kim, Ph.D.
Dr. Peter S. Kim, Ph.D.
Director
Director
104.33K
-10.60%
Dr. Natarajan Sethuraman, Ph.D.
Dr. Natarajan Sethuraman, Ph.D.
President of Research and Development
President of Research and Development
82.24K
-31.79%
Mr. Kory James Wentworth, CPA
Mr. Kory James Wentworth, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
31.84K
-27.89%
Mr. Nathan J. Dowden
Mr. Nathan J. Dowden
President, Chief Operating Officer
President, Chief Operating Officer
11.80K
-77.74%
Ms. Gina Chapman
Ms. Gina Chapman
Independent Director
Independent Director
--
--
Dr. Bernhardt (Bernie) Zeiher, M.D.
Dr. Bernhardt (Bernie) Zeiher, M.D.
Independent Director
Independent Director
--
--
收入明细
FY2025Q1
FY2024
FY2023
FY2023Q2
暂无数据
地区USD
名称
营收
占比
United States
20.56M
0.00%
业务
地区
暂无数据
股东统计
更新时间: 7月18日 周五
更新时间: 7月18日 周五
持股股东
股东类型
持股股东
持股股东
占比
Baker Bros. Advisors LP
12.82%
MPM Capital Inc.
11.54%
5AM Ventures
11.21%
T. Rowe Price Associates, Inc.
7.11%
F. Hoffman La Roche, Ltd.
6.77%
Other
50.54%
持股股东
持股股东
占比
Baker Bros. Advisors LP
12.82%
MPM Capital Inc.
11.54%
5AM Ventures
11.21%
T. Rowe Price Associates, Inc.
7.11%
F. Hoffman La Roche, Ltd.
6.77%
Other
50.54%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
28.19%
Investment Advisor
23.69%
Hedge Fund
14.14%
Corporation
11.35%
Venture Capital
11.34%
Private Equity
2.01%
Individual Investor
1.01%
Research Firm
0.54%
Pension Fund
0.22%
Other
7.51%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
226
35.27M
92.92%
-1.95M
2025Q1
237
37.05M
97.63%
-2.01M
2024Q4
222
37.20M
98.96%
+761.72K
2024Q3
209
35.09M
95.11%
-779.91K
2024Q2
193
34.68M
94.55%
+2.42M
2024Q1
185
31.33M
93.34%
-1.07M
2023Q4
174
31.30M
93.83%
-1.07M
2023Q3
167
31.14M
93.63%
-973.86K
2023Q2
154
30.75M
92.59%
+53.89K
2023Q1
141
30.00M
92.19%
-903.00K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Baker Bros. Advisors LP
4.87M
12.82%
--
--
Mar 31, 2025
MPM Capital Inc.
4.38M
11.54%
--
--
Mar 31, 2025
5AM Ventures
4.31M
11.35%
-100.00K
-2.27%
Jun 30, 2025
T. Rowe Price Associates, Inc.
2.70M
7.11%
-167.02K
-5.83%
Mar 31, 2025
F. Hoffman La Roche, Ltd.
2.57M
6.77%
-175.00K
-6.38%
Dec 31, 2024
Janus Henderson Investors
2.12M
5.59%
+41.29K
+1.98%
Mar 31, 2025
Merck & Co Inc
1.74M
4.58%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.73M
4.56%
+55.00
+0.00%
Mar 31, 2025
The Vanguard Group, Inc.
1.57M
4.14%
+111.36K
+7.62%
Mar 31, 2025
Fidelity Management & Research Company LLC
1.24M
3.27%
-160.10K
-11.44%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Virtus LifeSci Biotech Clinical Trials ETF
0.77%
iShares Neuroscience and Healthcare ETF
0.36%
First Trust Dow Jones Select MicroCap Index Fund
0.27%
Harbor Human Capital Factor US Small Cap ETF
0.1%
Federated Hermes MDT Small Cap Core ETF
0.05%
iShares Micro-Cap ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.03%
WisdomTree US SmallCap Fund
0.03%
Avantis US Small Cap Equity ETF
0.03%
Invesco Nasdaq Biotechnology ETF
0.03%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
占比0.77%
iShares Neuroscience and Healthcare ETF
占比0.36%
First Trust Dow Jones Select MicroCap Index Fund
占比0.27%
Harbor Human Capital Factor US Small Cap ETF
占比0.1%
Federated Hermes MDT Small Cap Core ETF
占比0.05%
iShares Micro-Cap ETF
占比0.04%
ProShares Ultra Nasdaq Biotechnology
占比0.03%
WisdomTree US SmallCap Fund
占比0.03%
Avantis US Small Cap Equity ETF
占比0.03%
Invesco Nasdaq Biotechnology ETF
占比0.03%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
